Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bonviva + OsteoStix NEM is a combination product marketed by anwerina Deutschland, primarily indicated for the treatment of postmenopausal osteoporosis. The product combines **Bonviva**, which contains the active pharmaceutical ingredient **ibandronic acid**, with **OsteoStix NEM**, a supplement containing **Natural Eggshell Membrane (NEM)**. Ibandronic acid is a nitrogen-containing bisphosphonate that acts by inhibiting farnesyl pyrophosphate synthase within osteoclasts, thereby reducing bone resorption and increasing bone mineral density. Natural Eggshell Membrane is a dietary ingredient rich in collagen, glycosaminoglycans (such as chondroitin sulfate and hyaluronic acid), and proteins, intended to provide nutritional support for bone matrix and joint health. The combination aims to provide both pharmacological inhibition of bone loss and structural support for the skeletal system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibandronic acid + natural eggshell membrane.